|
KMID : 1030220190200010006
|
|
Journal of Korean Diabetes
2019 Volume.20 No. 1 p.6 ~ p.9
|
|
|
Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018
|
|
Kim Jeong-Mi
Kim Sang-Soo
|
|
|
Abstract
|
|
|
|
In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the need for patient-centered management considering multimorbidity and individual patient preferences and barriers. Patients with type 2 diabetes with established atherosclerotic cardiovascular disease who fail to control blood glucose with the initial glucose-lowering medication are recommended a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist. For patients with chronic kidney disease and heart failure, SGLT2 inhibitors are recommended. In patients who need an injectable medication, GLP-1 receptor agonists are the preferred choice over insulin. In this section, we summarize “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).”
|
|
|
KEYWORD
|
|
|
Atherosclerosis, Cardiovascular disease, Diabetes mellitus, type 2, Hyperglycemia, Patient-centered care
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|